100
Participants
Start Date
October 5, 2020
Primary Completion Date
December 7, 2023
Study Completion Date
December 7, 2023
Atezolizumab
"Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes."
Paclitaxel
Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.
Bevacizumab
Will be administered intravenously over 30-90 minutes on Days 1 and 15.
Hopital Europeen Georges Pompidou, Paris
Hôpital Tenon AP-HP, Paris
Insitut de cancérologie Strasbourg Europe, Strasbourg
Klinikum Dessau (MVZ) - Frauenheilkunde, Dessau
University Hospital Essen, Essen
Universitätsklinikum Mannheim, Mannheim
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples
Hospital de Dénia-MarinaSalud, Denia
Hospital Universitario La Ribera, Alzira
Hospital de Sant Joan Despí - Moises Broggi, Barcelona
Hospital Universitari Dexeus, Barcelona
Hospital Universitario Clínico San Cecilio, Granada
Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria
Hospital Universitari Arnau de Vilanova, Lleida
Hospital Clínico San Carlos, Madrid
Hospital Ruber Juan Bravo, Madrid
Hospital Universitario Ramón y Cajal, Madrid
MD Anderson Cancer Center, Madrid
Complejo Hospitalario de Navarra, Pamplona
Hospital Universitari Sant Joan de Reus, Reus
Hospital Universitario San Juan de Alicante, Sant Joan d'Alacant
Hospital Universitario Virgen del Rocío, Seville
Hospital Quirón Valencia, Valencia
Hospital Universitario Miguel Servet, Zaragoza
Barts Health NHS Trust, London
Royal Cornwall Hospitals Nhs Trust, Truro
Hoffmann-La Roche
INDUSTRY
MedSIR
OTHER